Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Liquid Biopsy Market - Global Forecast to 2022 - Increasing Preference for Noninvasive Procedures

Research and Markets
Posted on: 11 Dec 17
Liquid Biopsy Market - Global Forecast to 2022 - Increasing Preference for Noninvasive Procedures

PR Newswire

DUBLIN, Dec. 11, 2017

DUBLIN, Dec. 11, 2017 /PRNewswire/ --

The "Liquid Biopsy Market - Global Forecast to 2022" report has been added to Research and Markets' offering.

The global liquid biopsy market is projected to reach USD 2,047.9 Million by 2022 from USD 715.7 Million in 2017, at a CAGR of 23.4%.

Increasing prevalence of cancer, increasing preference for noninvasive procedures, and availability of funding for liquid biopsy R&D are some of the key factors driving the growth of the market. Unclear Regulatory and reimbursement scenario is one of the major challenges faced by the market.

Based on circulating biomarkers the market is categorized into circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), cell-free DNA (cfDNA), extracellular vesicles (EVs) and other circulating biomarkers. The extracellular vesicles segment is the fastest-growing segment in the circulating biomarkers market during the forecast period. This is due to the growing interest in EV research from biofluids such as the blood and urine of cancer patients as a means of disease diagnosis and therapeutic monitoring.

Based on application, the liquid biopsy market is segmented into cancer and non-cancer applications (which include reproductive health and organ transplant diagnostics). The non-cancer application segment is expected to be the fastest-growing segment in the market during the forecast period. This is due to the growing application in noninvasive prenatal testing (NIPT), using cell-free DNA assays in the identification of trisomies (which includes 13, 16, and 18), gender identification, and other genetic abnormalities such as monosomy X and microdeletions. NIPT is also rapidly replacing amniocentesis in high-risk pregnancies, thus expanding its application.

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights

5 Market Overview

6 Liquid Biopsy Market, By Product And Service

7 Liquid Biopsy Market, By Circulating Biomarker

8 Liquid Biopsy Market, By Clinical Application

9 Liquid Biopsy Market, By Application

10 Liquid Biopsy Market, By End User

11 Liquid Biopsy Market, By Region

12 Competitive Landscape

13 Company Profiles

  • Biocept, Inc.
  • Bio-Rad Laboratories, Inc.
  • Genomic Health, Inc.
  • Guardant Health, Inc.
  • Illumina, Inc.
  • Mdxhealth Sa
  • Menarini-Silicon Biosystems
  • Myriad Genetics, Inc
  • Qiagen N.V.
  • Raindance Technologies, Inc
  • Roche Diagnostics
  • Thermo Fisher Scientific Inc.
  • Trovagene, Inc.

For more information about this report visit

Media Contact:

Research and Markets
Laura Wood, Senior Manager  

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716


View original content:

SOURCE Research and Markets

PR Newswire

Last updated on: 11/12/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.